Pasireotide (ditrifluoroacetate)

Pasireotide (SOM230) ditrifluoroacetate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5, pKi=8.2/9.0/9.1/[1][2].

Product Specifications

Product Name Alternative

SOM230 ditrifluoroacetate; Pasireotide TFA salt

UNSPSC

12352209

Target

Somatostatin Receptor

Type

Peptides

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Cancer-programmed cell death

Field of Research

Endocrinology; Cancer

Assay Protocol

https://www.medchemexpress.com/Pasireotide-ditrifluoroacetate.html

Purity

99.56

Solubility

DMSO : 100 mg/mL (ultrasonic) |H2O : 33.33 mg/mL (ultrasonic)

Smiles

O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.NCCCC[C@@H](C(N[C@H]1CC2=CC=C(C=C2)OCC3=CC=CC=C3)=O)NC([C@H](NC([C@H](C4=CC=CC=C4)NC([C@H]5N(C([C@H](CC6=CC=CC=C6)NC1=O)=O)C[C@H](OC(NCCN)=O)C5)=O)=O)CC7=CNC8=C7C=CC=C8)=O

Molecular Formula

C62H68F6N10O13

Molecular Weight

1275.25

References & Citations

[1]Lewis I, et, al. A novel somatostatin mimic with broad somatotropin release inhibitory factor receptor binding and superior therapeutic potential. J Med Chem. 2003 Jun 5;46 (12) :2334-44.|[2]Quinn TJ, et, al. Pasireotide (SOM230) is effective for the treatment of pancreatic neuroendocrine tumors (PNETs) in a multiple endocrine neoplasia type 1 (MEN1) conditional knockout mouse model. Surgery. 2012 Dec;152 (6) :1068-77.|[3]Imhof AK, et, al. Differential antiinflammatory and antinociceptive effects of the somatostatin analogs octreotide and pasireotide in a mouse model of immune-mediated arthritis. Arthritis Rheum. 2011 Aug;63 (8) :2352-62.

Shipping Conditions

Blue Ice

Storage Conditions

-20°C (Powder, sealed storage, away from moisture)

Scientific Category

Peptides

Clinical Information

Launched

Citation 01

Am J Pathol. 2018 Apr;188 (4) :981-994.|Commun Med (Lond) . 2022 Jul 1:2:80.|Hepatology. 2017 Oct;66 (4) :1197-1218.|Universidad De Salamanca. Biología y Clínica del Cáncer y Medicina Traslacional. 2022 Oct.|Basic Clin Pharmacol Toxicol. 2022 Sep;131 (3) :174-188.|J Clin Invest. 2024 October 1.